Gastric Cancer - Pipeline Review, H2 2018

Date: October 30, 2018
Pages: 1462
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GE94D3AFA18EN
Leaflet:

Download PDF Leaflet

Gastric Cancer - Pipeline Review, H2 2018
Gastric Cancer - Pipeline Review, H2 2018

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H2 2018, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.

Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 15, 85, 103, 12, 108, 18 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 11, 5, 1, 10 and 3 molecules, respectively.

Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


NOTE: Out of security concerns Global Markets Direct requires using corporate email address.
Introduction
Gastric Cancer - Overview
Gastric Cancer - Therapeutics Development
Gastric Cancer - Therapeutics Assessment
Gastric Cancer - Companies Involved in Therapeutics Development
Gastric Cancer - Drug Profiles
Gastric Cancer - Dormant Projects 1398
Gastric Cancer - Discontinued Products 1409
Gastric Cancer - Product Development Milestones 1413
Appendix 1424

LIST OF TABLES

Number of Products under Development for Gastric Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Gastric Cancer - Pipeline by 3SBio Inc, H2 2018
Gastric Cancer - Pipeline by AbbVie Inc, H2 2018
Gastric Cancer - Pipeline by AbGenomics International Inc, H2 2018
Gastric Cancer - Pipeline by Abion Inc, H2 2018
Gastric Cancer - Pipeline by Abpro, H2 2018
Gastric Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2018
Gastric Cancer - Pipeline by ADC Therapeutics SA, H2 2018
Gastric Cancer - Pipeline by Advenchen Laboratories LLC, H2 2018
Gastric Cancer - Pipeline by Alkermes Plc, H2 2018
Gastric Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2018
Gastric Cancer - Pipeline by Alteogen Inc, H2 2018
Gastric Cancer - Pipeline by Ambrx Inc, H2 2018
Gastric Cancer - Pipeline by amcure GmbH, H2 2018
Gastric Cancer - Pipeline by Amgen Inc, H2 2018
Gastric Cancer - Pipeline by ANP Technologies Inc, H2 2018
Gastric Cancer - Pipeline by Antikor Biopharma Ltd, H2 2018
Gastric Cancer - Pipeline by Argenx SE, H2 2018
Gastric Cancer - Pipeline by Array BioPharma Inc, H2 2018
Gastric Cancer - Pipeline by Asana BioSciences LLC, H2 2018
Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2018
Gastric Cancer - Pipeline by Astellas Pharma Inc, H2 2018
Gastric Cancer - Pipeline by AstraZeneca Plc, H2 2018
Gastric Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2018
Gastric Cancer - Pipeline by Avipep Pty Ltd, H2 2018
Gastric Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2018
Gastric Cancer - Pipeline by Bayer AG, H2 2018
Gastric Cancer - Pipeline by BeiGene Ltd, H2 2018
Gastric Cancer - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2018
Gastric Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2018
Gastric Cancer - Pipeline by Biocon Ltd, H2 2018
Gastric Cancer - Pipeline by Bioleaders Corp, H2 2018
Gastric Cancer - Pipeline by BioLineRx Ltd, H2 2018
Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Gastric Cancer - Pipeline by Bristol-Myers Squibb Co, H2 2018
Gastric Cancer - Pipeline by Camel-IDS NV, H2 2018
Gastric Cancer - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2018
Gastric Cancer - Pipeline by CARsgen Therapeutics Ltd, H2 2018
Gastric Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2018
Gastric Cancer - Pipeline by Celgene Corp, H2 2018

LIST OF FIGURES

Number of Products under Development for Gastric Cancer, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Top 10 Routes of Administration, H2 2018
Number of Products by Stage and Top 10 Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018

COMPANIES MENTIONED

3SBio Inc
AbbVie Inc
AbGenomics International Inc
Abion Inc
Abpro
Adaptimmune Therapeutics Plc
ADC Therapeutics SA
Advenchen Laboratories LLC
Alkermes Plc
Allist Shanghai Pharmaceutical Technology Co Ltd
Alteogen Inc
Ambrx Inc
amcure GmbH
Amgen Inc
ANP Technologies Inc
Antikor Biopharma Ltd
Argenx SE
Array BioPharma Inc
Asana BioSciences LLC
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Avipep Pty Ltd
Basilea Pharmaceutica Ltd
Bayer AG
BeiGene Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Betta Pharmaceuticals Co Ltd
Biocon Ltd
Bioleaders Corp
BioLineRx Ltd
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Camel-IDS NV
Cancer Prevention Pharmaceuticals Inc
CARsgen Therapeutics Ltd
CBT Pharmaceuticals Inc
Celgene Corp
Celldex Therapeutics Inc
Cellestia Biotech AG
Celltrion Inc
Celon Pharma SA
Chipscreen Biosciences Ltd
CMG Pharmaceutical Co Ltd
Cristal Therapeutics BV
CSPC Pharmaceutical Group Limited
CytomX Therapeutics Inc
Cytori Therapeutics Inc
Daiichi Sankyo Co Ltd
Dr. Reddy's Laboratories Ltd
Eddingpharm Inc
Eisai Co Ltd
Eli Lilly and Co
EOS Biosciences Inc
Erytech Pharma SA
Esperance Pharmaceuticals Inc
Exelixis Inc
F-star Biotechnology Ltd
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Five Prime Therapeutics Inc
FLX Bio Inc
Frost Biologic Inc
Genelux Corp
Genentech Inc
GeneScience Pharmaceuticals Co Ltd
Genmab A/S
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Glycotope GmbH
Guangdong Zhongsheng Pharmaceutical Co Ltd
Halozyme Therapeutics Inc
Hanmi Pharmaceuticals Co Ltd
Harbin Gloria Pharmaceuticals Co Ltd
Horizon Pharma Plc
Hummingbird Bioscience Pte Ltd
Hutchison MediPharma Ltd
Ildong Pharmaceutical Co Ltd
Immunicum AB
Immunomedics Inc
Immunomet Therapeutics Inc
Immunomic Therapeutics Inc
Incyte Corp
InnoCare Pharma Ltd
Inovio Pharmaceuticals Inc
Inspyr Therapeutics Inc
Intezyne Inc
Ipsen SA
Jeil Pharmaceutical Co Ltd
JHL Biotech Inc
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Kanion Pharmaceutical Co Ltd
Johnson & Johnson
Jounce Therapeutics Inc
JW Pharmaceutical Corp
Kazia Therapeutics Ltd
Konruns Pharmaceutical Co Ltd
Kringle Pharma Inc
Kyowa Hakko Kirin Co Ltd
LATITUDE Pharmaceuticals Inc
LegoChem Biosciences Inc
LinXis BV
Lycera Corp
MacroGenics Inc
MaxiVAX SA
MedImmune LLC
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Mersana Therapeutics Inc
Merus NV
MetaMax Ltd
Millennium Pharmaceuticals Inc
Mitsubishi Tanabe Pharma Corp
Moderna Therapeutics Inc
Molecular Partners AG
Molecular Targeting Technologies Inc
Moleculin Biotech LLC
Mycenax Biotech Inc
NanoCarrier Co Ltd
Novartis AG
OBI Pharma Inc
Oncobiologics Inc
OncoMed Pharmaceuticals Inc
OncoResponse Inc
Ono Pharmaceutical Co Ltd
Opsona Therapeutics Ltd
Orano Med LLC
Patrys Ltd
Pfizer Inc
Pharma Mar SA
Pieris Pharmaceuticals Inc
Polaris Pharmaceuticals Inc
Prescient Therapeutics Ltd
Puma Biotechnology Inc
Rhizen Pharmaceuticals SA
Richter Gedeon Nyrt
Sanofi
Scancell Holdings Plc
Seattle Genetics Inc
Selecta Biosciences Inc
SELLAS Life Sciences Group Inc
Sequella Inc
Shanghai Henlius Biotech Co Ltd
Shionogi & Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Simcere Pharmaceutical Group
Sino Biopharmaceutical Ltd
Sorrento Therapeutics Inc
Supratek Pharma Inc
SynCore Biotechnology Co Ltd
Synthon Holdings BV
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Co Ltd
Takis Srl
Tarveda Therapeutics Inc
Terns Pharmaceuticals Inc
Tessa Therapeutics Pte Ltd
Toray Industries Inc
Triumvira Immunologics Inc
Tyrogenex Inc (Inactive)
United BioPharma Inc
Unum Therapeutics Inc
Vaxon Biotech
Venus Remedies Ltd
Viracta Therapeutics Inc
Wuhan YZY Biopharma Co Ltd
Xencor Inc
XuanZhu Pharma Co Ltd
Zhejiang Jianfeng Group Company Ltd
Zymeworks Inc
Skip to top


Gastric Cancer - Pipeline Review, H1 2018 US$ 2,500.00 Apr, 2018 · 1283 pages
Rectal Cancer - Pipeline Review, H2 2018 US$ 2,000.00 Aug, 2018 · 113 pages
Gastric Ulcers - Pipeline Review, H2 2018 US$ 2,000.00 Sep, 2018 · 44 pages
Ureter Cancer - Pipeline Review, H2 2018 US$ 2,000.00 Oct, 2018 · 206 pages
Rectal Cancer - Pipeline Review, H1 2018 US$ 2,000.00 Feb, 2018 · 112 pages

Ask Your Question

Gastric Cancer - Pipeline Review, H2 2018
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: